Comparing GreenLight PVP and HoLEP Beyond 5 Years: A Systematic Review of Long-Term Functional Outcomes and Reoperation Rates - Beyond the Abstract ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
Does Adjuvant Immune Checkpoint Inhibition Therapy Have a Future in Operable Bladder Cancer? December 18, 2025 Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical ...
December 16, 2025 Is the era within which a TURP was performed associated with differences in reoperation rates, specific surgical side effects, or the requirement for BPH medicat ...
Prostate cancer, while commonly diagnosed in early forms, remains the second leading cause of cancer mortality in the United States and Europe. 1 For patients who die of prostate cancer, some will be ...
Ariana Smith discusses autologous pubovaginal slings for stress urinary incontinence treatment, highlighting this century-old procedure as a durable mesh-free alternative that remains underutilized in ...
Read the Full Video Transcript Diane Newman: Hello, I'm Diane Newman. I'm a continence nurse specialist and I'm an adult nurse practitioner. I've been practicing in a pelvic floor dysfunction, seeing ...
David Staskin discusses the COURAGE trial, a phase three study evaluating the efficacy of Vibegron, a beta-3 adrenergic receptor agonist, in men with BPH and persistent OAB symptoms despite ...
Read the Full Video Transcript Diane Newman: Welcome to UroToday's Bladder Health Center of Excellence. I am Diane Newman, the center's Editor, and Adjunct Professor of Urology and Surgery at the ...
Amy Pearlman discusses penile rehabilitation strategies following prostate cancer treatment. Dr. Pearlman shares her expertise on vacuum pump therapy as a crucial component of penile rehabilitation.
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Combination Lenvatinib-Tislelizumab for Fumarate Hydratase-Deficient Renal Cell Carcinoma - Wen Kong
Pedro Barata interviews Wen Kong about lenvatinib plus tislelizumab for first-line treatment of fumarate hydratase (FH)-deficient renal cell carcinoma. Dr. Kong shares results from a single-center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback